Automated Insulin Delivery Versus Standard of Care in the Management of People Living with Type 1 Diabetes and HbA1c <8%: A Cost–Utility Analysis in The Netherlands
Authors' conclusion
For PwT1D in The Netherlands, who had a baseline HbA1c <8% and do not reach glycemic targets, AID system initiation was projected to improve long-term clinical outcomes and reduce both direct costs for the treatment of diabetes-related complications and productivity losses.
Study context
- Population
- People with T1D and baseline HbA1c <8% not reaching glycemic targets, The Netherlands; baseline characteristics and treatment effects from the MiniMed 780G arm of a prospective multicenter study
- Comparison
- Automated insulin delivery (AID) vs SoC
- Outcome
- Incremental cost-utility ratio (cost per QALY gained)
- Follow-up
- 50 years
Methodological detailsIQVIA CORE Diabetes Model, 50-year time horizon, societal perspective, costs discounted 3%/year, effects 1.5%/year, sensitivity analyses
- IQVIA CORE Diabetes Model
- 50-year time horizon
- Societal perspective
- Costs discounted 3%/year, effects 1.5%/year
- Sensitivity analyses
Main finding
As reported in the abstract
Cost-utility
Incremental cost-utility ratio
29,836 EUR per QALY gained
based on combined costs
Quality-adjusted life expectancy gain
0.99 QALYs
Cost-utility
Incremental combined cost
28,635 EUR
higher acquisition costs, partially offset by reduced complication and indirect costs
Further findings
| Outcome | Improvement (years) |
|---|---|
| Life expectancy · 50 years | 0.52 |
Original publication
Automated Insulin Delivery Versus Standard of Care in the Management of People Living with Type 1 Diabetes and HbA1c <8%: A Cost–Utility Analysis in The Netherlands. Diabetes Technol Ther. Published 18 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →